Effect of Human Amniotic Epithelial Cells on Children With Spastic Cerebral Palsy
Effect of Intrathecal Transplant of Human Amniotic Epithelial Cells on Children With Spastic Cerebral Palsy
Sponsor: Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Listed as NCT03107975, this PHASE1 trial focuses on Spastic Cerebral Palsy and remains ongoing. Sponsored by Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China, it has been updated 6 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
-
May 2019 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Enrolling By Invitation → Unknown Status
-
Jun 2018 — May 2019 [monthly]
Enrolling By Invitation PHASE1
▶ Show 1 earlier version
-
May 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE1
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
- The Second Affiliated Hospital of Fujian Medical University
For direct contact, visit the study record on ClinicalTrials.gov .